ÂÜÀòÂÒÂ×

Michael Karl Bauer is an experienced professional in the biopharmaceutical industry with a robust background in operations, clinical development, and strategic management. Currently, Michael serves as a member of the Board of Directors for Myricx Bio, Numab Therapeutics AG, and as a guest to the Board at Alentis Therapeutics. Additionally, Michael holds the position of Partner and Venture Partner at Novo Holdings. Prior to these roles, Michael had an extensive tenure at Genmab, where several senior vice president positions were held, including Head of Operations R&D and SVP Clinical Development. Michael's career began with positions at Novo Nordisk and BankInvest, focusing on pharmacology, scientific licensing, and investment evaluation in the biotech sector. Michael has academic credentials from prestigious institutions, holding a PhD from the University of Göttingen and an MSc from the University of Hohenheim, complemented by executive education from Harvard Business School.